Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Cisco Systems

Chevron

Goldman Sachs

Travelers

Walgreens

Undervalued Dow stocks can be difficult to find, but this article is looking at seven that investors should consider buying right now. The post 7 Seriously Undervalued Dow Stocks to Buy Before Wall Street Catches On appeared first on InvestorPlace.

7 Seriously Undervalued Dow Stocks to Buy Before Wall Street Catches On

The FDA is expected to give its decision on Merck's (MRK) Keytruda sBLA for adjuvant stage IB-IIIA NSCLC, following complete surgical resection, on Jan 29, 2023.

Merck (MRK) Keytruda Adjuvant Lung Cancer sBLA Accepted by FDA

Zoetis

There is more to the comparison, and in the sections below, we discuss why we believe that ZTS stock will offer better returns than MRK stock in the next three years.

Is There A Better Pick Over Merck Stock In Animal Health Space?

Bank of New York Mellon

Moody's

Marsh & McLennan

Verizon

If any investor has stood the test of time, it is Warren Buffett. For years, the “Oracle of Omaha” has had a rock-star-like presence in the investing world.

5 Warren Buffett Dividend Stocks That Should Dodge Runaway Inflation

Merck & Co., Inc. (NYSE:MRK ) Goldman Sachs 43rd Annual Global Healthcare Conference June 13, 2022 6:20 PM ET Company Participants Rob Davis - President & Chief Executive Officer Dean Li - Executive Vice President & President of Merck Research Laboratories Conference Call Participants Chris Shibutani - Goldman Sachs Chris Shibutani Welcome, everybody to the Goldman Sachs Healthcare Conference. It's fantastic to see everybody in person here.

Merck & Co., Inc. (MRK) CEO Rob Davis Presents at the Goldman Sachs 43rd Annual Global Healthcare Conference (Transcript)

While the stock market continues to be pummeled, one Dow Jones company seems to be holding its own. In the past month, shares of pharma giant Merck & Co. Inc. ( MRK , Financial) have been flat while the Dow is down nearly 5% and the Dow U.S. Pharmaceutical Index has sunk about 6%.

Potential Merck Targets Now a Lot Cheaper

RAHWAY, N.J.--(BUSINESS WIRE)-- #MRK--FDA Accepts Application for Merck's KEYTRUDA as Adjuvant Therapy for Stage IB-IIIA Non-Small Cell Lung Cancer Following Complete Surgical Resection

FDA Accepts Application for Merck's KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Stage IB (≥4 centimeters)-IIIA Non-Small Cell Lung Cancer Following Complete Surgical Resection

- Merck's retrosynthesis AI software 'SYNTHIA™ retrosynthesis software' accelerates Standigm's synthesis capability SEOUL, South Korea , June 9, 2022 /PRNewswire/ -- Standigm Inc. ("Standigm"), the leading workflow artificial intelligence (AI) drug discovery company, today announced the signing of a Memorandum of Understanding (MOU) with Merck Korea, for AI-based drug discovery research. The MOU signing took place on May 30 at the headquarters of Standigm, attended by Sojeong Yun, CEO of Standigm, and Stephen Namkoo Lee, the Head of Science and Lab Solutions, Life Science business sector of Merck Korea.

Standigm Signs MOU with Merck Korea for AI drug Discovery Research

Bank of America

Kraft Heinz

Coca-Cola

Kroger

7 Warren Buffett Stocks Pay Big Dividends and Will Survive Higher Interest Rates

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Robert M. Davis, chief executive officer and president, and Dean Y. Li, president, Merck Research Laboratories, will participate in a fireside chat at the live 2022 Goldman Sachs 43rd Annual Global Healthcare Conference. The conversation will take place Monday, June 13, 2022, at 3:20pm PT // 6:20pm ET. Investors, analysts, members of the media and the general public are invi

Merck to Participate in the 2022 Goldman Sachs 43rd Annual Global Healthcare Conference

Merck & Co., Inc. (NYSE:MRK ) ASCO 2022 Oncology Event Conference Call June 7, 2022 8:00 AM ET Company Participants Dean Li - Executive Vice President & President of Merck Research Laboratories Eliav Barr - Chief Medical Officer & Head of Global Clinical Development of Merck Research Laboratories Eric Rubin - Senior Vice President of Global Clinical Oncology & Early-stage Oncology Jannie Oosthuizen - Senior Vice President & President Merck U.S. Human Health Peter Dannenbaum - Vice President of Investor Relations Conference Call Participants Steve Scala - Cowen & Company Daina Graybosch - SVB Leerink Terence Flynn - Morgan Stanley Mohit Bansal - Wells Fargo Chris Shibutani - Goldman Sachs Seamus Fernandez - Guggenheim Securities Evan Seigerman - BMO Capital Markets Dean Li [Call starts abruptly] to be here today. As we discussed, Eliav will outline the progress made since the last ASCO sort of investor meeting we had in 2021.

Merck & Co., Inc. (MRK) Management Presents at ASCO 2022 Oncology Event Conference (Transcript)

Merck & Co., Inc. (NYSE:MRK) has just pulled back to the $90 level after its recent all-time high, a level that served as prior resistance.

Merck Stock Could Be the Right Play for Bullish Traders

RAHWAY, N.J. & MIAMI--(BUSINESS WIRE)---- $MRK #MRK--Merck and Ridgeback Announce New Data For Investigational LAGEVRIO™ (molnupiravir) From Phase 3 MOVe-OUT Study

Merck and Ridgeback Announce New Data For Investigational LAGEVRIO™ (molnupiravir) From Phase 3 MOVe-OUT Study

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside the United States and Canada, will provide a detailed overview of the company's oncology portfolio and pipeline at an investor event today at the 2022 American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago at 7 a.m. CT/8 a.m. ET. At this year's ASCO, data for Merck's oncology portfolio and pipeline will be presented from nearly 120 abstracts in more than 25 cancer types. At the investor event, the company wi

Merck to Hold Investor Event to Highlight Oncology Portfolio and Pipeline

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Adjuvant Treatment With KEYTRUDA Demonstrates Improvement in DMFS in Stage IIB or IIC Melanoma in Phase 3 KEYNOTE-716 Trial

Adjuvant Treatment With Merck's KEYTRUDA® (pembrolizumab) Demonstrates Statistically Significant & Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients With Resected Stage IIB or IIC Melanoma in Phase 3 KEYNOTE-716 Trial

Lockheed Martin

Lumen Technologies

McDonald's

PepsiCo

These blue-chip stocks with dividends offer a healthy income stream and potentially strong gains through capital appreciation. The post 7 Blue-Chip Stocks With Dividends to Add to Your Q2 Buy List appeared first on InvestorPlace.

7 Blue-Chip Stocks With Dividends to Add to Your Q2 Buy List

AbbVie

Bristol-Myers

BioNTech SE

Moderna

Pfizer

These were the industry's bestsellers last year, but how long can they stay on top?

Can the Best-Selling Drugs of 2021 Repeat Their Performance?

General Motors

Intel

Recent declines on Wall Street create the perfect opportunity to invest in these three best long-term stocks. The post The 3 Best Long-Term Stocks to Add to Your Q2 Buy List appeared first on InvestorPlace.

The 3 Best Long-Term Stocks to Add to Your Q2 Buy List

Broadcom

Conagra Brands

Chubb

Prudential Financial

QUALCOMM

Dump speculative, over-priced stocks and buy strong businesses during a bear market because good investments will reward investors. The post 7 Stocks to Buy and Hold Forever in This Bear Market appeared first on InvestorPlace.

7 Stocks to Buy and Hold Forever in This Bear Market

Merck, currently priced at about 12.5x FW PE, is still undervalued by a sizable margin. Growth from pipeline drugs and especially Molnupiravir is not properly priced in, leading to a PEG ratio of only 0.78.

Merck: Still Undervalued After 22% Return

Citizens Financial Group

DTE Energy

NextEra Energy

Realty Income Corp

Phillips 66

Last week's final reading of a negative 1.5% gross domestic product for the first quarter (the first such print since the second quarter of 2020) was even worse than the preliminary reading, and it is a good sign that things could get worse before they get better.

7 Highest-Yielding Goldman Sachs Conviction List Stocks Can Thrive in a Recession

Merck's market-topping 3% dividend yield isn't the sole reason to buy shares.

Why This Fast-Growing Dividend Stock Is a Buy

It's a close call between these two big drugmakers.

Better Dividend Stock: Pfizer or Merck?

Lagevrio sales for COVID-19 were $3247 million in Q1 2022. Merck's gross profit was $10,567 million in the first quarter, up 39.2% year-over-year.

Merck: Investment Opportunity

Johnson & Johnson

Despite the market sell-off, these biotech stocks have held up exceptionally well.

News for Merck Stock (MRK)